You are viewing: US Immunotherapy Drugs Market analysis
Part of: Immunotherapy Drugs Market (Global)

The US Immunotherapy Drugs Market was valued at $70400 Million in 2024 and projected to reach to $129400 Million by 2029, representing a compound annual growth rate of 12.9%. The US immunotherapy drugs market is poised for sustained expansion through 2029, driven by increasing cancer incidence, growing FDA approvals for novel immunotherapies, and expanding applications beyond oncology into autoimmune and infectious diseases.

US Immunotherapy Drugs Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Immunotherapy Drugs Market Trends and Insights

  • The US represents a critical hub for immunotherapy innovation, driven by advanced healthcare infrastructure, substantial R&D investments, and high adoption rates of cutting-edge cancer and autoimmune treatments.
  • The US market's expansion reflects increasing prevalence of cancer diagnoses, growing patient awareness, and accelerating approvals of novel checkpoint inhibitors and CAR-T therapies. During the 2024-2029 forecast period, the US immunotherapy drugs market will expand at a compound annual growth rate of 12.9%, significantly outpacing many global peers.
  • This growth trajectory is supported by robust reimbursement policies, a strong pipeline of combination therapies, and expanding indications across oncology and immunology.
  • The US market benefits from early access programs, substantial healthcare spending, and a competitive landscape dominated by leading biopharmaceutical companies investing heavily in next-generation immunotherapies. Key drivers propelling the US market include rising incidence of melanoma, lung cancer, and hematologic malignancies, coupled with improved patient outcomes and extended survival rates.
  • The US immunotherapy drugs market is also benefiting from increased clinical trial activity, real-world evidence generation, and growing adoption in earlier treatment lines, positioning the country as a global leader in immunotherapy commercialization through 2029..

Key Market Statistics

  • CAGR (2024-2029) 12.9% CAGR
  • Market Size, 2024 ~USD 70400 Million
  • Forecast, 2029 ~USD 129400 Million
  • Country US

US Immunotherapy Drugs Market Overview

Market Valuation :

The US immunotherapy drugs market is valued at $70.4 billion in 2024, representing the world's largest and most mature immunotherapy market with significant revenue concentration among leading biopharmaceutical companies.

Projected Growth :

Expected to reach $129.4 billion by 2029 with a CAGR of 12.9%, demonstrating sustained double-digit growth driven by expanding treatment indications, improved patient outcomes, and increasing healthcare spending on oncology and immunology.

Innovation Hub :

The US serves as the global epicenter for immunotherapy R&D, with the highest concentration of clinical trials, FDA approvals, and breakthrough designations, attracting substantial venture capital and pharmaceutical investment in checkpoint inhibitors and CAR-T therapies.

Healthcare Infrastructure :

Advanced diagnostic capabilities, comprehensive insurance coverage, and established treatment protocols across major cancer centers and academic medical institutions enable rapid adoption of novel immunotherapy agents and combination therapies.

US Immunotherapy Drugs Market Dynamics

  • Key growth catalysts include personalized medicine approaches, biomarker-driven patient selection, and combination therapy strategies that enhance efficacy and patient outcomes. Market dynamics are shaped by favorable reimbursement policies, robust healthcare spending, and strong competition among major pharmaceutical players.
  • However, pricing pressures, patent expirations of blockbuster drugs, and biosimilar competition will influence market growth rates.
  • The US market will continue to lead global immunotherapy adoption, with emerging therapies in immuno-oncology and next-generation checkpoint inhibitors driving revenue expansion..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • The US immunotherapy drugs market is valued at $70.4 billion in 2024 and will nearly double to $129.4 billion by 2029, growing at a 12.9% CAGR.
    • The US market is driven by high cancer incidence, advanced healthcare infrastructure, robust reimbursement, and accelerating FDA approvals of novel immunotherapies.
    • Checkpoint inhibitors and CAR-T cell therapies dominate the US market, with expanding indications in earlier treatment lines and combination regimens.
    • The US immunotherapy drugs market benefits from substantial R&D investment, early access programs, and a competitive landscape of leading biopharmaceutical companies.

    Immunotherapy Drugs Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment OTHER IMMUNOTHERAPY DRUGS (Type)
    Forecast Period 2024-2029
    Growth Rate CAGR of 15.3% from 2024 to 2029
    Largest Segment HOSPITALS (End User)
    Market Size Base Year (Billions) ~USD 284.92 (2024)
    Revenue Forecast (Billions) ~USD 580.6 (2029)
    Segments Covered Type, Application, Route Of Administration, End User

    US Immunotherapy Drugs Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Antibody Drugs
    • Cancer Vaccines
    • Inhibitor Drugs
    • Interferons & Interleukins
    • Other Immunotherapy Drugs

    By Application

    • Autoimmune & Inflammatory Diseases
    • Cancer
    • Hematology
    • Neurology
    • Osteology
    • Other Applications

    By Route Of Administration

    • Intravenous Route Of Administration
    • Other Route Of Administration
    • Other Routes Of Administration
    • Subcutaneous Route Of Administration

    By End User

    • Hospitals
    • Long-Term Care Facilities
    • Other End Users

    Target Audience

    • Pharmaceutical & Biotech Companies : Require detailed US market data to guide R&D investments, clinical trial planning, regulatory strategies, and commercial launch decisions for immunotherapy candidates targeting the American oncology and immunology markets.
    • Healthcare Investment Firms : Need comprehensive US market analysis to evaluate investment opportunities in immunotherapy companies, assess portfolio company performance, and identify emerging growth segments within America's $70+ billion immunotherapy sector.
    • Medical Device & Diagnostics Companies : Seek US market intelligence to understand companion diagnostic requirements, biomarker-driven treatment selection, and integration opportunities with immunotherapy drugs in the American healthcare landscape.
    • Healthcare Payers & Providers : Require market forecasts and treatment trend data to optimize formulary decisions, budget allocation, clinical pathway development, and patient access programs for immunotherapy drugs across US healthcare systems.
    • Market Research & Consulting Firms : Need authoritative US immunotherapy market data to support client advisory services, competitive benchmarking, market entry strategies, and industry reports for stakeholders across the American healthcare value chain.

    Reasons to Buy this Report

    • Market Size & Forecast Data : Access precise US market valuations ($70.4B in 2024, $129.4B in 2029) with detailed CAGR analysis to support strategic planning, investment decisions, and competitive positioning in the world's largest immunotherapy market.
    • Competitive Landscape Intelligence : Identify leading US biopharmaceutical players, market share distribution, and competitive strategies specific to the American market to inform partnership opportunities, M&A decisions, and product development priorities.
    • Regulatory & Reimbursement Insights : Understand FDA approval trends, breakthrough designations, and US insurance coverage policies that directly impact market access, pricing strategies, and commercial success for immunotherapy products in the US healthcare system.
    • Growth Driver Analysis : Evaluate US-specific factors including cancer prevalence, treatment adoption rates, healthcare infrastructure maturity, and R&D investment levels to identify high-potential market segments and expansion opportunities.
    • Strategic Market Positioning : Leverage US market insights to benchmark performance against competitors, identify unmet clinical needs, and develop targeted go-to-market strategies for immunotherapy products in America's advanced healthcare ecosystem.

    Frequently asked questions

    What is the current size of the US immunotherapy drugs market in 2024?

    The US immunotherapy drugs market is valued at $70.4 billion in 2024, representing a significant portion of global immunotherapy spending.

    What is the projected size of the US immunotherapy drugs market by 2029?

    The US immunotherapy drugs market is projected to reach $129.4 billion by 2029, reflecting an 84% increase from 2024 levels.

    What is the CAGR for the US immunotherapy drugs market from 2024 to 2029?

    The US immunotherapy drugs market is expected to grow at a compound annual growth rate of 12.9% during the 2024-2029 forecast period.

    What are the primary drivers of growth in the US immunotherapy drugs market?

    Key growth drivers in the US market include rising cancer incidence, FDA approvals of novel therapies, expanded treatment indications, robust reimbursement policies, and increased clinical adoption of checkpoint inhibitors and CAR-T therapies.

    Which therapeutic areas dominate the US immunotherapy drugs market?

    Oncology, particularly melanoma and non-small cell lung cancer, dominates the US immunotherapy drugs market, with growing expansion into hematologic malignancies and autoimmune diseases.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the immunotherapy drugs market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the immunotherapy drugs market. The secondary sources referred to for this research study include publications from government sources, such as National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), World Health Organization (WHO), European Pharmaceutical Review, American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), European Medicines Agency (EMA), and the Alliance for Regenerative Medicine (ARM). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the immunotherapy drugs market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

    Immunotherapy  Drugs Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the immunotherapy drugs market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the immunotherapy drugs and other dependent submarkets. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Immunotherapy  Drugs Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the immunotherapy drugs market.

    Market Definition

    Immunotherapy drugs are a broad category of therapeutic agents that help stimulate the body's immune system to combat diseases. These drugs include antibody therapies, cell & gene therapy, inhibitor drugs, and other drugs such as oncolytic viral therapy and cancer vaccines. These drugs are engineered to enhance the immune response or counteract the immune system's regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cells. Immunotherapy drugs are used to treat various medical conditions, including cancer, autoimmune diseases, hematology, osteology, neurology, and other therapy areas (such as ophthalmology, dermatology, and cardiovascular disorders).

    Stakeholders

    • Research Institutes
    • Pharmaceutical & Biotechnology Companies
    • Venture Capitalists and Investors
    • Contract Development & Manufacturing Organizations
    • Government Associations
    • Healthcare Associations/Institutes
    • Business Research & Consulting Service Providers

    Report Objectives

    • To define, describe, and forecast the immunotherapy market based on type,  application, route of administrration, end user, and region
    • To provide detailed information about the drivers, restraints, opportunities, and challenges influencing the market growth
    • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall immunotherapy drugs market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of market segments in North America, Europe, the Asia Pacific (APAC), Latin America, Middle East and Africa
    • To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
    • To track and analyze competitive developments, such as partnerships, collaborations, agreements, and acquisitions, in the immunotherapy drugs market
    • Micromarkets are the further segments and subsegments of the immunotherapy drugs market.
    • Core competencies of companies are captured in terms of the key developments, market shares, and key strategies adopted to sustain their positions in the market.

    Available Customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    • Company Information: Detailed analysis and profiling of additional market players (up to five)
    • Geographic Analysis: Further breakdown of the Rest of Europe market, by country, based on approvals and feasibility. Further breakdown of the Rest of Asia Pacific market, by country, based on approvals and feasibility

    Get the Full Immunotherapy Drugs Market Report

    Full forecast, segment splits, and company analysis for all Immunotherapy Drugs Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status